Sickle Cell Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with an inherited blood disorder affecting hemoglobin, such as sickle cell disease, beta-thalassemia, or alpha-thalassemia (all types are considered).
- You are 2 years old or older at the time your health information is collected for the study.
- People of any gender or ethnic background, and with other health conditions, are welcome to participate.
Who may not be able to join:
- You have previously been treated with a stem cell transplant or gene therapy.
- You are under 2 years old at the time your health information is collected for the study.
- You (or your legal guardian, if you are a child) are unwilling or unable to give consent to take part in the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Petros Kountouris, PhD, Cyprus Institute of Neurology and Genetics
Phone: 22392623
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Genetic modifiers in haemoglobinopathies through GWAS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.